- What has been your biggest challenge working on m2M project?
The m2M project is highly complex, involving multiple partners across different countries and disciplines. Keeping a clear overview of the progress across the different work packages while aligning the technical developments toward a common objective, bioprinting functional cartilage tissues, can be challenging.
However, the strong commitment of the consortium and the regular coordination meetings have greatly facilitated collaboration. From Metatissue’s side, a key responsibility has been ensuring the reliable supply of human-derived biomaterials to support the development of bioinks and cellular systems used across the consortium. We increased production capacity and maintained a strict quality control to minimize batch-to-batch variability, ensuring that partners receive high-quality materials quickly and consistently to support their experimental work.
2. How do you think the m2M project can make a difference in the bioprinting field?
The m2M project has the potential to significantly advance the field of cartilage bioprinting by combining innovative bioprinting strategies with biologically active human-derived biomaterials. Cartilage regeneration remains a major clinical challenge due to its limited self-healing capacity. By developing new bioinks and bioprinting strategies capable of recreating the structural and biochemical microenvironment of cartilage tissue, the project aims to generate more functional and durable engineered cartilage constructs. This approach could improve the fidelity and performance of bioprinted tissues, bringing the field closer to clinically relevant solutions.
3. In your opinion, how can the project help patients and strength the European biomanufacturing capacity while fostering collaboration between industry and clinicians?
The m2M project addresses an important unmet clinical need: the repair of cartilage damage caused by trauma, aging, or degenerative diseases such as osteoarthritis. By developing advanced biofabrication technologies capable of producing functional cartilage tissues, the project may contribute to future regenerative therapies that restore joint function and improve patients’ quality of life. At the same time, the project strengthens the European biomanufacturing ecosystem by advancing biomaterial production, scalable bioprinting technologies, and translational tissue engineering approaches. The collaboration between industry, academic institutions, and clinicians ensures that the technologies developed are aligned with real clinical needs.
4. For you, what is the main result that m2M will deliver?
One of the main expected outcomes of the m2M project is the development of a robust bioprinting platform capable of producing structured, biomimetic cartilage constructs with controlled architecture and biological functionality. This includes the integration of advanced bioinks, printing strategies, and cellular systems to recreate cartilage tissue organization. From Metatissue’s perspective, an important result is also demonstrating how human-derived biomaterials can enhance cell behavior and matrix formation in bioprinted cartilage constructs, contributing to more physiologically relevant engineered tissue.
5. We reached the 1-year mark of the project; how do you see the progress made?
After the first year, the project has made very positive progress. Several foundational steps have been successfully completed, including the development and optimization of biomaterials, the establishment of initial cell culture and bioink formulations, and the advancement of the bioprinting technologies required to fabricate cartilage constructs. The collaboration between partners has been very active, enabling rapid exchange of knowledge and alignment between biomaterial development, printing technologies, and biological validation. These early achievements provide a strong basis for the next phases of the project, where the focus will increasingly shift toward generating and validating functional bioprinted cartilage tissues.